Healthcare Strategy Consulting
Build a winning game
plan for growth
Kx Advisors is a different type of healthcare consultancy
Kx Advisors provides growth strategy consulting services to help healthcare executives achieve critical business goals. We live and breathe healthcare growth strategy, and our focus drives results. A highly collaborative approach helps us develop pragmatic solutions for leading pharmaceutical, biotechnology, medical device, health IT, and digital health clients, while our data-driven insights give those clients the tools to compete and win across the healthcare industry.Learn More
Deep sector expertise with a growth strategy focus
“Kx has impressed everyone in our organization. They are really smart people who understand our business and get stuff done.”
“The Kx team raised the bar for analytical rigor in our organization. They set the standard for what good looks like and we now use them for all our commercial due diligence work.”
“We don’t need to spend time educating Kx on our business. They just get it and go. Their recommendations are always crystal clear and easy to communicate to our senior executives”
Publications and Recent Insights
Explore our publications and
Health Equity: The Kx Research Approach and Case Study
April 27, 2023 • Advanced healthcare treatments require patients to pass through multiple specialists or undergo significant surgical procedures.
Evolving Considerations for Segmenting Aesthetic Practices
April 20, 2023 • The global aesthetics market for product sales has more than doubled in the past 10 years, from $6B to $12.5B. Simultaneously, the number of US aesthetics practices has exploded to exceed 40,000 today.
Alzheimer’s Disease Therapeutics and Diagnostics – Parallel Advancements for Patient Care
April 20, 2023 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).